Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer

BACKGROUND: With approval of anti-PD-1/PD-L1, metastatic non-small cell lung cancer (NSCLC) has entered the era of immunotherapy. Since immune-related adverse events (irAEs) occur commonly in patients receiving anti-PD-1/PD-L1, the landscape of death causes may have changed in metastatic NSCLC. We a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yijun, Yao, Zhuoran, Zhang, Jianhui, Han, Chang, Kang, Kai, Zhao, Ailin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691859/
https://www.ncbi.nlm.nih.gov/pubmed/36439167
http://dx.doi.org/10.3389/fimmu.2022.1058819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691859/
https://www.ncbi.nlm.nih.gov/pubmed/36439167
http://dx.doi.org/10.3389/fimmu.2022.1058819

Ejemplares similares